Valuation: Ovation Science Inc.

Market Cap 8L 5L 5L 4L 4L 5.28Cr 8L 53.26L 20.77L 2.57Cr 20.47L 20.02L 8.93Cr P/E 2024
-2.68x
P/E 2025 -2.26x
Enterprise Value 10L 7L 6L 6L 5L 6.73Cr 10L 67.87L 26.47L 3.28Cr 26.08L 25.52L 11Cr EV / Sales 2024
13.2x
EV / Sales 2025 25.7x
Free-Float
76.54%
Yield 2024 *
-
Yield 2025 -
Current month+33.33%
1 month+33.33%
3 months-42.86%
6 months-50.00%
Current year-50.00%
1 month 0.02
Extreme 0.02
0.02
Current year 0.02
Extreme 0.015
0.04
1 year 0.02
Extreme 0.015
0.05
3 years 0.01
Extreme 0.01
0.08
5 years 0.01
Extreme 0.01
0.14
10 years 0
Extreme 0
0.65
Manager TitleAgeSince
Director of Finance/CFO 63 30/10/2023
Chief Executive Officer 77 04/10/2017
Director TitleAgeSince
Director/Board Member 77 04/10/2017
Director/Board Member 63 04/10/2017
Director/Board Member 86 02/02/2018
Date Insider Type Main position Quantity % Market Cap.
07/04/25 Buy

Director

1,00,000 0.2642%
31/01/25 Other

Director

0 0%
31/01/25 Buy

Director

1,00,000 0.2642%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-66.67%0.00% 5L
-3.10%-3.28%-1.63%-10.29% 23TCr
-2.73%+1.62%+37.42% - 5.02TCr
+3.50%-4.02%+108.10% - 906.34Cr
-3.41%-0.84%+22.34%-52.23% 744.68Cr
+1.80%-1.49%-11.66%+15.31% 491.39Cr
-3.64%+2.23%-35.28%-31.78% 465.78Cr
-2.02%-2.42%-9.43%-9.31% 391.42Cr
-0.36%-2.87%-29.72%-47.74% 338.77Cr
-9.82%-11.39%-29.58%-52.61% 261.38Cr
Average -1.98%+0.68%-1.61%-23.58% 3.18TCr
Weighted average by Cap. -2.81%+1.05%+6.95%-12.30%

Financials

2024 2025
Net sales 1L 80.34T 70.66T 65.64T 60.37T 77.8L 1L 8L 3L 37.95L 3L 3L 1.32Cr 67.89T 48.17T 42.37T 39.36T 36.2T 46.65L 69.1T 5L 2L 22.75L 2L 2L 78.94L
Net income -5L -3L -3L -3L -2L -3.13Cr -5L -31.63L -12.34L -1.53Cr -12.15L -11.89L -5.3Cr -6L -4L -4L -4L -3L -4.34Cr -6L -43.76L -17.07L -2.12Cr -16.82L -16.45L -7.34Cr
Net Debt 3L 2L 2L 2L 1L 1.82Cr 3L 18.38L 7L 88.88L 7L 7L 3.08Cr 2L 1L 1L 1L 1L 1.45Cr 2L 14.61L 6L 70.65L 6L 5L 2.45Cr
Logo Ovation Science Inc.
Ovation Science Inc. is a Canada-based drug development company. The Company develops topical and transdermal cannabidiol (CBD)/ tetrahydrocannabinol (THC) and other cannabinoid products which are out-licensed and also distributed under its own brands; ARLO CBD Beauty and InVibe MD (wellness line); all powered by its patented Invisicare skin delivery technology. The Company manufactures, distributes, sells, markets, sub-licenses and promotes products formulated with Invisicare, containing cannabinoids, hemp seed oil or synthetic derivatives of cannabis. The Company has developed topical and transdermal creams and lotions made with CBD, THC and combinations thereof plus hemp seed oil. Invisicare is a patented polymer-based technology for topical and transdermal skincare products. ARLO CBD Beauty offers science-based skincare solutions. Invibe MD offers a health and wellness product line infused with hemp-derived CBD and developed using Invisicare drug delivery technology.
Employees
-
Date Price Change Volume
23/26/23 CA$0.000000 - 100
  1. Stock Market
  2. Stocks
  3. OVAT Stock